Recs

2

1 Reason to Buy Amarin Right Now, and 1 Reason to Sell

By | More Articles
November 14, 2012 | Comments (0)

Amarin's (Nasdaq: AMRN  ) share price has yo-yoed after the company gained Food and Drug Administration approval for its triglyceride-lowering drug, Vascepa, this summer. However, investors are still interested in this exciting biotech story, and there are reasons to be both bullish and bearish on this stock.

In the following video, Austin Smith talks with health care analyst and author of our premium research report on Amarin, Max Macaluso, about one specific reason to buy shares of this company and one reason to sell.

The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the success of Vascepa is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Austin Smith has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 2112196, ~/Articles/ArticleHandler.aspx, 5/20/2013 9:26:27 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 15,354.40 121.18 0.00%
S&P 500 1,667.47 17.00 0.00%
NASD 3,498.97 33.73 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/17/2013 4:00 PM
AMRN $7.14 Down -0.09 +0.00%
Amarin Corp plc (A… CAPS Rating: ***
VVUS $12.30 Down -0.24 +0.00%
VIVUS, Inc. CAPS Rating: **
DNDN $4.01 Up +0.04 +0.00%
Dendreon Corp CAPS Rating: **
AZN $51.56 Down +0.00 +0.00%
AstraZeneca plc (A… CAPS Rating: ****

Advertisement